Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Trial to screen children for type 1 diabetes now available in Northern Ireland
Children in Northern Ireland are now eligible for a trial screening programme that will identify those at high risk of developing type 1 diabetes in the future.
Launched in England, Scotland and Wales in November 2022, the trial is the first of its kind for the UK which will lay the groundwork for the development of a potential future UK-wide screening programme, transforming how type 1 diabetes is identified and managed in its earliest stages.
Funded by JDRF together with Diabetes UK, ELSA (EarLy Surveillance for Autoimmune diabetes) aims to recruit 20,000 children, aged 3-13 years, to assess their risk of developing type 1 diabetes through at-home finger-prick blood tests. Home testing kits are now available to families throughout Northern Ireland. Around 1 in 100 children will require follow-up venous blood testing, available at the Southern Health and Social Care Trust.
The ELSA research team are able to identify people at high risk of type 1 diabetes by testing for markers in the blood, called autoantibodies – tools used by the immune system to earmark insulin-producing cells for destruction. Autoantibodies are associated with the development of type 1 diabetes, and can appear in the blood years, or sometimes decades, before people begin to experience any symptoms.
Risk of type 1 diabetes increases with the number of different autoantibodies present in the blood. Children with two or more autoantibodies have an 85% chance of developing type 1 diabetes within 15 years, and it is almost certain that they will develop the condition in their lifetime.
Children found to be at risk and their families will be offered support and education – including information on symptoms and management – to help prepare them for the diagnosis of type 1 diabetes.
Families will also be offered the opportunity to be followed up in the long-term to enable closer monitoring and potentially to start insulin treatment sooner. Research in Europe and the US has found that the extra support and monitoring screening programmes can offer, dramatically reduces the risk of being diagnosed in diabetic ketoacidosis (DKA) – a life-threatening condition.
While type 1 diabetes is currently managed using insulin, there are new immunotherapy treatments on the horizon that could prevent or delay the condition. Children found to be at high risk through ELSA could be invited to take part in research testing these treatments. One such treatment, teplizumab, which has been found to delay a diagnosis of type 1 diabetes by up to three years, was approved in the U.S. last year and is currently under review in the UK.
Preventative treatments for type 1 diabetes can only be effective when combined with screening programmes to identify those at risk. By offering vital insights that could make routine, widespread screening for type 1 diabetes a reality in the UK, ELSA could be critical to help unleash the benefits of teplizumab if approved here.
Edelle Irwin, whose six-year-old son is taking part in ELSA, said: “When my son Shane was rushed to hospital and diagnosed with type 1 diabetes, we had no idea what to expect. Seeing my seven-year-old hooked up to all those machines, surrounded by nursing staff in a hospital bed will be forever etched in our minds. If we had recognised the symptoms earlier, that day would not have turned into the emergency situation it was.
“Now that ELSA is available in Northern Ireland, I’m relieved to be getting my youngest son screened for type 1. He also has autism and screening would allow us to plan in the case of a diabetes diagnosis and management, given the extra challenges his sensory issues may cause. I would urge other families in Northern Ireland to get their children screened too so that they have the tools to keep their children safe and possibly avoid a similar situation to us.”
Parth Narendran, Professor of Diabetes Medicine, and Dr Lauren Quinn, Clinical Research Fellow at the University of Birmingham, said: “The ELSA team are delighted to open the ELSA study in Northern Ireland. Over 9,000 children from across England, Scotland and Wales are already part of the study. ELSA aims to screen 20,000 children to find out their risk of type 1 diabetes. Screening and monitoring help prevent emergency presentations with type 1 diabetes. Families identified at risk are offered education and participation in monitoring programmes, the opportunity to participate in clinical trials and potentially also therapies to delay the onset of type 1 diabetes if these are licensed in the UK.”
Rachel Connor, Director of Research Partnerships at JDRF UK, said: “We are delighted that the ELSA study is expanding to Northern Ireland, building on the incredible success of the screening programme in the rest of the UK. The dedicated research team will ensure children in Northern Ireland at risk of type 1 and their families are supported and monitored to give them the best possible start in their journey with the condition.
“At JDRF, we believe it is vital that everyone in the UK has access to the latest advances in type 1 diabetes research. This important move by the ELSA study paves the way for children in Northern Ireland to be included in the testing and roll out of future immunotherapies to slow the progression of type 1, such as teplizumab.”
For further information on ELSA, please visit elsadiabetes.nhs.uk
Screening aims to find people in the earliest stages of developing type 1 diabetes.
"As soon as I found out that screening is now available in Northern Ireland, I reached out to the ELSA team here in Northern Ireland and ordered a test kit."
We’ve written a letter to Gillian Keegan MP, Secretary of State for Education, asking her to make exemptions to the Government’s policy on banning mobile phones in schools. We thought you might like to read it.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
